Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

NCRI 2010 /
Systems biomedicine

7th - 10th Nov 2010

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 28.12.10
Views: 4069

Prof Edison Liu - Genome Institute of Singapore

Cancer is a complex disease which is caused by multiple genetic and epigenetic changes. In addition, cancer is a genetic moving target capable of mutating into resistant or more aggressive forms. Prof Liu's team have employed a strategy of using genomic data to reconstruct systems maps of critical regulatory networks, identify critical nodes in the oncogeneic network and target them in order to induce apoptosis and cell differentiation. This genome-to-system approach was used to quickly uncover the complex mechanisms of action of DZNep, an S-adenosylhomocysteine hydrolase inhibitor that induces apoptosis in cancer cells but not in normal cells. Prof Liu explains how EZH2 levels and genomic mapping will be used to decide patient eligibility for this treatment and notes that considering this therapy targets a process rather than a specific cancer; it will be useful when treating a number of different cancers.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation